| 8.83 -0.865 (-8.92%) | 03-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.92 |
1-year : | 11.68 |
| Resists | First : | 9.35 |
Second : | 10 |
| Pivot price | 9.37  |
|||
| Supports | First : | 8.31 |
Second : | 6.91 |
| MAs | MA(5) : | 9.36 |
MA(20) : | 9.24 |
| MA(100) : | 9.24 |
MA(250) : | 13.11 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 59.4 |
D(3) : | 64.7 |
| RSI | RSI(14): 44.8 |
|||
| 52-week | High : | 25.13 | Low : | 8.31 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BIS ] has closed above bottom band by 6.6%. Bollinger Bands are 13.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.42 - 9.49 | 9.49 - 9.54 |
| Low: | 8.66 - 8.72 | 8.72 - 8.77 |
| Close: | 8.74 - 8.84 | 8.84 - 8.92 |
ProShares UltraShort Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index.
Sat, 28 Mar 2026
UltraShort NASDAQ Biotechnology declares quarterly distribution of $0.0686 - MSN
Wed, 11 Mar 2026
Navigating Headwinds: The ProShares UltraShort Biotech ETF Faces Sector Momentum - AD HOC NEWS
Wed, 14 May 2025
Top Performing Leveraged/Inverse ETFs: 05/11/2025 - ETF Trends
Tue, 19 Nov 2024
Top Performing Leveraged/Inverse ETFs: 11/17/2024 - ETF Trends
Mon, 05 Dec 2022
3 “Oversold” ETFs to Start the Week - ETF Database
Fri, 27 May 2016
ProShares Launches Pair Of Geared Biotech ETFs - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|